Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

ements, among others, relating to our future capital requirements and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and unc
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIRâ„¢ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ) ... Market Monitor: North American Dermatology Diagnostic Devices Market" ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic surgeries ... resulted in fueling the overall demand of the ... these dermatology devices is to assist in identifying ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... second quarter of fiscal year 2015 results on Thursday, January ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3ResMed To Announce Second Quarter 2015 Results 2
... Index (BMI) Rebound Age, Can Predict Heart Disease and Calls for ... Children,s ... The results from the newest study,in a continuum of research on childhood ... reason for pediatricians to begin,measuring and monitoring body mass index (BMI) in ...
... Tissue Oncology, Society held in Seattle, Washington demonstrates clinical ... single agent in patients with ... chemo-insensitive sarcomas, NEW YORK, Nov. ... preliminary data demonstrating the,tolerability and clinical activity of KRX-0401 (perifosine) in ...
Cached Medicine Technology:New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions 2New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 2Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 3Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 4Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 5Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma 6
(Date:12/19/2014)... These vanadium reserves are mostly found in ... tons of vanadium were produced globally in 2013, up ... at 6.7% AAGR during the period from 2001 to ... the largest consumer, accounted for more than 90% of ... and the chemical industry. , View Full Report at ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- New research warns parents ... young lives at risk. Nearly half of teen drivers killed ... that were at least 11 years old and often lacked important ... Eighty-two percent of teen drivers killed in crashes were in ... six to 10 years old, 31 percent were in cars 11 ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Injectable drug ... double the suicide attempt rate of other substance users, ... use is associated with the risk of suicide attempt ... the University of Montreal, said in a university news ... users. We wanted to know who among substance users ...
(Date:12/19/2014)... Raleigh, NC (PRWEB) December 19, 2014 Surviving ... asbestos and EPA information indicates that these pipes can leach ... to go to the full story on the Surviving ... to the erosion of natural asbestos deposits, decaying water mains ... in drinking water. , To protect consumers from ...
(Date:12/19/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief financial officer search ... top executive search firm in the healthcare industry, B. ... executives into organizations. , Johnson Memorial Hospital is ... the residents of Johnson County and the surrounding areas. ...
Breaking Medicine News(10 mins):Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 2Health News:Marketresearchreports.biz: Global Vanadium Usage Increased at AAGR of 6.7% between 2001 and 2013 3Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... on knowing when you,re ready to drive again , , WEDNESDAY, ... get behind the wheel again after orthopedic surgery or injury, but ... turning the key. , Orthopedic surgeons weigh in on the issue ... Joint Surgery . , "Deciding when a patient can return ...
... (OTC Pink Sheets: SNDY ) is pleased to announce that ... by over 10% compared to the same time period for 2007. ... $28,509 for the same month last year. This marks the second ... of October. , , The Mammo ...
... Dec. 10 GeneGo, Inc., a leading,provider of software ... ,today announced that A*STAR,s Singapore Immunology Network (SIgN) has ... will have access,to GeneGo,s MetaCore, training and advanced support. ... all SIgN researchers. , ...
... Three Skilled Nursing Facilities , , ... intense 18-month selection process, a proven commitment to clinical ... records (EMR) throughout Metropolitan Jewish Health System,s (Metropolitan) skilled ... Metropolitan, a nationally recognized nonprofit organization, operates Metropolitan ...
... Services, Goodwill, , , ... MDZ ), a leading provider of products and services ... 2008 performance. , Based on preliminary information, MDS expects ... $1,210 million to $1,220 million and adjusted EBITDA in the range ...
... While They,re Still Healthy Enough to Qualify , ... you,ve put off getting long term care insurance, should you ... health plan? "I wouldn,t advise it," says Denise Gott, Chairman ... of the nation,s most experienced long term care insurance agencies. ...
Cached Medicine News:Health News:Returning to the Road Tricky After Injury 2Health News:Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year 2Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
Housed in a small lightweight, flame retardant plastic cases, meters are equipped with a convenient multiposition handle/stand. Measure microcirculation in 1 cubic mm of tissue for real-time assessme...
... Strips are non-invasive and theres no expensive ... Perfusion Monitor Strips are simple to use. ... reliable. The advanced liquid crystal technology has ... range of applications including biofeedback, nerve blocks, ...
... a high performance laser doppler system ... (tissue) blood perfusion. This latest generation ... introduced with its multi-channel brother (Oxyflo), ... processing and laser doppler flowmetry providing ...
Transcranial vascular DWL doppler....
Medicine Products: